Want to see IN:ALIVUS full AI Analyst Report?
Top Page
Glenmark Life Sciences Limited
(ALIVUS)
Select Model
Select Model
Rating:77Outperform
Price Target:
₹1,556.00
▲(68.98% Upside)
Action:Reiterated
Date:08/11/26
The score is driven primarily by strong financial performance (rapid FY2026 growth, robust margins, and an exceptionally low-debt balance sheet). Technicals are supportive due to a strong uptrend, but overbought indicators (high RSI/Stoch) temper the rating. Valuation is a moderate drag given the 27.98 P/E and low ~0.36% dividend yield.
Positive Factors
Revenue Acceleration
A >100% revenue jump in FY2026 signals material commercial traction and successful scaling of API sales. Sustained higher volumes can amortize fixed costs, support durable margin improvement, and enable long‑term customer qualification and retention across regulated markets.
Negative Factors
Weak Cash Conversion
FCF materially trailing net income indicates working capital and capex are absorbing cash despite profit growth. If persistent, weak cash conversion can limit organic reinvestment, constrain distributions, and force external funding when scaling production for new contracts.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Acceleration
A >100% revenue jump in FY2026 signals material commercial traction and successful scaling of API sales. Sustained higher volumes can amortize fixed costs, support durable margin improvement, and enable long‑term customer qualification and retention across regulated markets.
Read all positive factors
Glenmark Life Sciences Limited (ALIVUS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹170.06B
Dividend Yield0.36%
Average Volume (3M)11.74K
Price to Earnings (P/E)28.3
Beta (1Y)0.88
Revenue Growth7.93%
EPS Growth21.51%
CountryIN
Employees2,272
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)22.17
Shares Outstanding122,771,450
10 Day Avg. Volume13,738
30 Day Avg. Volume11,742
Financial Highlights & Ratios
PEG Ratio1.32
Price to Book (P/B)3.59
Price to Sales (P/S)4.69
P/FCF Ratio46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)55.17
Revenue Forecast (FY)₹28.45B
Glenmark Life Sciences Limited Business Overview & Revenue Model
Company Description
Alivus Life Sciences Limited, a Mumbai, India-headquartered entity established in 2001, operates as a subsidiary of Nirma Limited. Having rebranded from Glenmark Life Sciences Limited in December 2024, the company specializes in the development, p...
How the Company Makes Money
Glenmark Life Sciences primarily makes money by manufacturing and selling active pharmaceutical ingredients (APIs) and intermediates to pharmaceutical companies and other healthcare manufacturers that use these inputs to produce finished dosage fo...
Glenmark Life Sciences Limited Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
93
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.90B | 25.52B | 22.83B | 21.61B | 18.85B | 15.37B |
| Gross Profit | 5.56B | 11.37B | 12.43B | 11.47B | 9.80B | 8.47B |
| EBITDA | 4.02B | 8.32B | 6.86B | 6.71B | 5.92B | 4.84B |
| Net Income | 2.72B | 5.64B | 4.71B | 4.67B | 3.52B | 3.13B |
Balance Sheet | ||||||
| Total Assets | 36.38B | 39.83B | 28.50B | 27.02B | 19.97B | 17.26B |
| Cash, Cash Equivalents and Short-Term Investments | 6.53B | 7.83B | 3.01B | 3.80B | 1.40B | 307.68M |
| Total Debt | 1.13B | 567.71M | 171.48M | 193.57M | 9.33B | 210.00K |
| Total Liabilities | 6.23B | 6.51B | 5.18B | 5.64B | 12.44B | 13.24B |
| Stockholders Equity | 30.15B | 33.32B | 23.32B | 21.38B | 7.53B | 4.02B |
Cash Flow | ||||||
| Free Cash Flow | 2.39B | 2.59B | 2.85B | 1.43B | 3.20B | 1.44B |
| Operating Cash Flow | 4.33B | 5.66B | 4.14B | 3.13B | 3.88B | 1.95B |
| Investing Cash Flow | -7.95B | -5.71B | -1.16B | -1.54B | -687.34M | -505.18M |
| Financing Cash Flow | -649.40M | -641.34M | -2.79B | -3.88B | -2.14B | -1.37B |
Glenmark Life Sciences Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ₹170.06B | 28.27 | ― | 0.36% | 7.93% | 21.51% | |
68 Neutral | ₹2.48T | 84.58 | ― | 0.32% | 16.35% | 26.84% | |
66 Neutral | ₹301.97B | 60.46 | ― | 0.14% | 78.33% | 182.61% | |
64 Neutral | ₹225.41B | 33.77 | ― | 0.19% | 24.83% | 36.88% | |
60 Neutral | ₹1.06T | 97.23 | ― | 0.10% | 22.62% | 114.66% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹36.01B | -1,339.02 | ― | 0.45% | 15.49% | -112.78% |
* General Sector Average
IN:ALIVUS
Glenmark Life Sciences Limited
1,348.65
415.88
44.59%
IN:DIVISLAB
Divi's Laboratories Limited
9,190.00
3,120.64
51.42%
IN:GRANULES
Granules India Limited
872.50
333.72
61.94%
IN:LAURUSLABS
Laurus Labs Ltd.
1,923.00
1,029.48
115.22%
IN:NEULANDLAB
Neuland Laboratories Ltd.
22,522.85
6,350.64
39.27%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
715.30
39.40
5.83%
Glenmark Life Sciences Limited Corporate Events
Alivus Life Sciences Boosts Capital with ESOP Share Allotment
Jul 30, 2026
Alivus Life Sciences Limited has approved the allotment of 32,000 equity shares with a face value of Rs. 2 each to eligible employees exercising options under its Employee Stock Option Scheme, 2021. This move modestly increases the company’s...
Alivus Life Sciences Schedules Q1 FY2026-27 Earnings Call
Jul 23, 2026
Alivus Life Sciences Limited has announced the schedule for its Q1 FY2026-27 earnings call, set for Friday, July 31, 2026, from 8:30 a.m. to 9:30 a.m. IST. The company has circulated dial-in details, including universal and international toll-free...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.